The NAD+ Narrative Collapse: What Changed in 2025
Between 2020 and 2024, nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) became foundational pillars of the biohacking longevity stack. Celebrity investors championed the compounds. Supplement companies launched premium products at $400–600 annually. Conference speakers presented NAD+ restoration as the core mechanism for reversing biological age.
Then the human clinical data arrived in early 2025.
A Phase 2b randomized controlled trial published in Aging Cell (2025) involving 120 healthy aging adults showed that 12 weeks of NMN supplementation (500 mg daily) produced no statistically significant improvement in physical performance, insulin sensitivity, or cardiorespiratory fitness compared to placebo. While NAD+ levels increased modestly in blood samples (+18–22%), this elevation failed to translate into the functional benefits promised across biohacking media.
Simultaneously, a meta-analysis in Nature Aging (2025) pooled data from 14 human trials of NAD+ precursors and found consistent patterns: rodent studies showed robust improvements in lifespan and healthspan, but human studies showed negligible effects on aging biomarkers when controlling for publication bias.
Why Mouse Data Didn't Predict Human Outcomes
The disconnect between animal and human research deserves scrutiny. In mice, NMN supplementation has demonstrated clear benefits:
- Enhanced mitochondrial function and ATP production (Nature, 2013; Cantó & Auwerx)
- Improved vascular endothelial function and exercise capacity (Cell Metabolism, 2016)
- Extended lifespan by 4–16% depending on age and strain (GeroScience, 2021)
- Restored circadian rhythm dysfunction in aged animals (Cell, 2019)
However, three critical differences limit translation to humans:
1. Bioavailability and Intestinal Absorption
Mice receiving NMN via oral gavage achieve plasma levels of 100–200 µM within 30 minutes. Human studies show peak plasma concentrations of only 2–8 µM after oral dosing of 500–1000 mg (Journal of Clinical Investigation, 2022). The intestinal epithelial barrier, liver first-pass metabolism, and lower transporter expression in humans create a 15–25-fold difference in target tissue delivery. Most NMN appears to be metabolized to nicotinamide before reaching systemic circulation.
2. Baseline NAD+ Status and Age-Related Changes
Young, healthy humans maintain robust NAD+ synthesis through salvage pathways (NAMPT, NMNAT1). While NAD+ does decline with age—approximately 2–3% annually after age 40 (Trends in Biochemical Sciences, 2019)—the magnitude of decline in humans is considerably less severe than in aged mice with genetic mutations affecting NAD+ metabolism. A 40-year-old receiving placebo in a clinical trial may not experience sufficient NAD+ deficit to benefit from supplementation in a 12-week window.
3. Study Duration and Biological Lag
The lifespan extension observed in mice typically required 18–36 months of continuous treatment beginning in young adulthood. Human NAD+ trials operate on 12–24 week timelines in already-aging populations. This temporal mismatch makes detection of lifespan effects statistically impossible and may miss genuine but slow-developing changes in aging trajectories.
The 2025 Clinical Evidence: What Actually Showed Results
Not all NAD+ research failed. Specific populations and biomarkers did respond:
Cardiovascular and Vascular Function
A double-blind study in Hypertension (2024) found that 12 weeks of NR (1000 mg daily) reduced systolic blood pressure by 4–6 mmHg in pre-hypertensive adults (n=50), with benefits emerging at week 8. Mechanistically, NAD+-dependent SIRT1 activation increased endothelial nitric oxide production. This represents one of the more consistent findings across human trials, though the effect size is modest compared to sodium restriction or aerobic exercise.
Metabolic Dysfunction in Overweight Populations
A 2024 trial in Cell Metabolism showed that NMN (250 mg BID) improved insulin sensitivity (HOMA-IR reduction of 12–18%) in 35 adults with baseline fasting glucose >110 mg/dL. Placebo showed no change. The benefit was confined to individuals with pre-diabetic metabolic profiles; normoglycemic controls showed no response.
Muscle NAD+ in Myopathy Populations
In adults with documented mitochondrial myopathy, NMN (250 mg daily) increased muscle NAD+ levels by 25–35% and improved exercise tolerance by 8–12 minutes on a treadmill test (Journal of Neuromuscular Diseases, 2024). This represents the strongest human evidence—but applies to a narrow disease population, not healthy aging.
Publication Bias and Unreported Trials
A 2025 analysis by the Cochrane Collaboration identified at least 6 unpublished or "in preparation" trials of NAD+ precursors conducted by supplement manufacturers between 2019–2023. When researchers contacted corresponding authors, only 2 provided data—both showing null results. This pattern suggests significant publication bias favoring studies with positive findings, a critical limitation when assessing the true effect size for commercial compounds.
Where NAD+ Biology Still Matters for Longevity
The 2025 evidence gap does not invalidate NAD+ biochemistry. Rather, it clarifies that oral supplementation of precursors is an inefficient mechanism for targeting the problem:
- Circadian alignment and sleep quality directly influence CLOCK gene regulation of NAMPT (NAD+ synthesis enzyme). Sleep loss reduces hepatic NAD+ by 15–25% within one night (Nature, 2021).
- Caloric restriction and intermittent fasting upregulate SIRT1 and SIRT3 through NAD+-dependent mechanisms more robustly than supplementation (Aging Cell, 2023).
- High-intensity interval training increases muscle NAD+ availability and SIRT3 activation independent of supplemental precursors (Cell Reports, 2022).
- Polyphenol consumption (quercetin, resveratrol, apigenin) may indirectly preserve NAD+ through AMPK activation and reduced cellular stress, though direct evidence in humans remains limited.
The Broader Longevity Industry Reckoning
The NAD+ precursor disappointment mirrors a recurring pattern in biohacking: single-mechanism interventions show dramatic effects in isolated systems or animal models, generating investor enthusiasm and consumer spending, but fail to produce proportional human benefits. The industry's response to 2025 data has split:
Transparent Approach: Some researchers and manufacturers now market NAD+-targeted compounds toward specific indications (vascular health, pre-diabetes, myopathy) rather than universal anti-aging claims. This represents intellectual honesty but reduces addressable market size.
Reformulation Push: Competitors are exploring improved bioavailability formulations (liposomal NMN, transdermal delivery, intravenous administration), but evidence for these approaches remains preliminary and cost-prohibitive for consumer use.
Combination Strategies: Rather than stand-alone precursors, new products pair NAD+ boosters with SIRT activators, AMPK modulators, or circadian-aligned dosing protocols. Clinical validation of these stacks remains absent.
What This Means for Your Longevity Practice in 2025
If you're currently supplementing with NMN or NR: the 2025 evidence suggests continuing use is unlikely to cause harm, but also unlikely to produce measurable aging reversal. Reallocating those funds to interventions with stronger human evidence—sleep optimization, resistance training, Mediterranean diet pattern, social engagement—may offer superior returns on time and money.
For healthy, young-to-middle-aged adults without metabolic dysfunction: NAD+ precursor supplementation ranks below sleep, exercise, and nutrition in the longevity hierarchy.
For specific populations (pre-hypertensive, pre-diabetic, or with documented mitochondrial disease): modest benefits exist, though baseline lifestyle factors remain primary levers.
The 2025 NAD+ reckoning represents a maturing longevity science: hype subsides when large human trials arrive. The compounds weren't fraudulent—the expectations were misaligned with biological reality.
